Vaccination with autologous HIV-1-pulsed DCs feasible in HIV
|
| Publicado: 4 de marzo de 2010 |
Vista previa del contenido
|
|
A phase I study including 23 patients with chronic HIV infection who had been off highly active antiretroviral therapy for at least the previous 2 years, examined immunization with autologous dendritic cells (DCs) pulsed with a high dose of heat-inactivated autologous HIV-1. The participants were randomized to 3 immunizations, given once every 2 weeks, with myeloid DCs that were unpulsed ("placebo group") or pulsed with 10(9) autologous heat-inactivated HIV-1 virus particles ("vaccinated group"). Vaccination was safe and well tolerated, with 3 patients experiencing enlargement of local lymph nodes. At week 24, viral load declined -0.20 log10 in the vaccinated group while it increased 0.21 log10 in the placebo cohort. At week 48, viral load dropped -0.31 log10 in the vaccinated group and increased 0.34 log10 in the placebo cohort. The proportion of patients with a decrease in viral load of at least 0.5 log did not differ significantly between the...
|